Quick Answer
Arcutis Biotherapeutics, Inc. reported Total Assets of $432.97 million for fiscal year 2025.
Arcutis Biotherapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $432.97M | +24.1% |
| 2024 | $348.89M | +2.2% |
| 2023 | $341.37M | -24.0% |
| 2022 | $449.27M | +10.1% |
| 2021 | $408.15M | +36.8% |
| 2020 | $298.27M | +178.7% |
| 2019 | $107.01M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $370.98M | -15.2% | +5.3% |
| June 30, 2025 | $352.43M | -20.8% | +2.4% |
| March 31, 2025 | $344.11M | -28.1% | -1.4% |
| December 31, 2024 | $348.89M | +2.2% | -20.2% |
| September 30, 2024 | $437.35M | +49.3% | -1.7% |
| June 30, 2024 | $444.76M | +38.7% | -7.1% |
| March 31, 2024 | $478.54M | +26.1% | +40.2% |
| December 31, 2023 | $341.37M | -24.0% | +16.5% |
- Arcutis Biotherapeutics, Inc. showed an increase of +24.1% in Total Assets compared to the prior fiscal year.
- Over the 2019–2025 period, Arcutis Biotherapeutics, Inc.’s total assets has grown by 304.6% (from $107.01 million to $432.97 million).
- The most recent figure is from Arcutis Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: